cn:::r: c(cid:173)mG>
`c.... I mr
`o-<
`-1(')
`-10 oz
`en:!!
`-IC
`-m
`'"Oz
`c .... r (cid:173)
`)>)>
`- l r m,
`c
`1J
`;u
`
`0 ..... m
`(')
`.....
`< m
`0
`;u
`c
`m
`;u
`
`PLAINTIFFS'
`TRIAL EXHIBIT .
`PTX0892
`
`PTX0892-00001
`
`1
`
`CIP2094
`Argentum Pharmaceuticals LLC v. Cipla Ltd.
`IPR2017-00807
`
`

`

`N
`0
`0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`US Population by Payer Segment
`
`316,128,639 Total Lives
`
`27,647,239
`
`mt Commercial - 59.59%
`m Medicaid- 10.37%
`
`tt Managed Medicaid- 9.31%
`m Medicare- 11.17%
`@~@ Employer- 10.12%
`
`II Uninsured- 8.75%
`
`90°/o discount required to be listed in Medicaid and managed
`Medicaid -> not a target for Dymista
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480362
`
`2
`
`

`

`M
`0
`0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`Dymista Commercial Coverage (June 2014)
`92 Million lives unrestricted
`
`158,942,300 Lives
`
`t:!i Preferred -32%
`
`mm Covered - 26%
`
`t Restricted (PA/ST) - 12%
`
`:t:~ Not Covered- 30%
`
`Source : Managed Markets Insights & Technologies, June 2014
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480363
`
`3
`
`

`

`-.::t
`0
`0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`Dymista Medicare Part D Coverage (June 2014)
`15 Million lives unrestricted
`
`Total Lives= 35,323,700
`
`:ll Preferred - 33%
`
`1m Covered - 11%
`
`Restricted (PA/ST) 1%
`
`1@ Not Covered - 26%
`
`Not Listed 29%
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480364
`
`4
`
`

`

`II)
`0
`0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`Unrestricted market access is key
`
`• 316 million lives in the US (All segments)
`
`• Dymista® has achieved unrestricted coverage in 1 07 million
`lives (Commercial and Medicare Part D)
`
`1/3 rd of the US Population
`
`• Losing big payers will negatively affect market share
`
`• Ultimate goal is to have unrestricted access and tier 2 preferred
`status when it makes financial sense
`Doctors can prescribe Dymista without limitation to patients as initial therapy
`or who have failed on any other brand I generic
`Limited co pay for the patient with Tier 2 or Tier 3
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480365
`
`5
`
`

`

`cn:::r:
`c-
`mG>
`c.... I mr
`o-<
`-I(')
`-10
`oz
`en:!!
`-IC
`-m
`"'llz
`c-1 r-
`)>)>
`-lr
`m c
`"'tJ
`;u
`0
`-I
`m
`(')
`-I
`<
`m
`0
`;u
`c
`m
`;u
`
`w1
`w5
`w9
`w13
`w17
`w21
`w25
`w29
`w33
`w37
`w41
`w45
`w49
`w53
`w57
`w61
`w65
`w69
`w73
`w77
`w81
`w85
`w89
`
`0~
`~'<
`()
`.?
`~ (''-!
`,<:- ~
`(')0
`'-1 ..;
`~ ~ <..;
`1,.
`Q'-1
`~ ..;
`~
`\§>'<..;
`0~
`~'<
`..;
`()
`~ ('<
`..;
`,<:-
`(')0
`'.?.
`~ "?
`:0_..
`'.?.
`"?
`
`s
`m
`c ?>
`
`)>
`"'tJ
`-I
`><
`0
`I\)
`~
`(X)
`
`0 w
`a>
`a>
`
`0
`
`::-:o:•:-:•:•:-:•:.:•:-:•:.:·:·:·:·>:•:-:•:.:•:•:-:
`::•:•:•:-:•:•:-:•:·:·:·:•:-:•:•:•:•l':•:·:•:-:•:•:•:•l':•:·:•:
`::·:·:·:-:•:•:-:-:·:·:·:·:-:•:•:-:-:-:•:·:·:-:•:•:-:-:-:•:·:·:·:·:(cid:173)
`·~·;•:•:o;•;•:-:•;o;•;•;•:o;•;•:•;•;>;•;•:•:o;•;•:•;•;>;•;•:•:•;•;•.
`~-;·;·;o;•;•;.;•;•;•;•;•;o;•;•:•;•;.;•;•;•;o;•;•:•;•;.;•;•;•;•;•;o;•:•l
`~·;•;•;o;·:·"t:•;•;•;•;•;o;•;•:•;•;.;•;•;•;o;•;•:•;•;.;•;•;•;•;•;o;•;•"t:·:•:•;•;•;o;•;
`:~;s=~-=~~~~~;:~:s=~;:~u;:~:s=~;:~u;:~;£;.'i!~~~~~;s:
`:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.:.c.:.:.:.:.:.:.:.:.c.:.:.:.:.: .. -.:.:.:.:.:.:.:.: .. -.:.
`;.!.:.: .. -.:.:u.:.:.:.:o!>! .. -.:.:u.:.:o!>! .. -.:.:u.:.:.:.! .. -.:.:u.:.:.:.! .. -.:.:u.:.:.
`
`:.:~.:.:.:.t.:.u.:.:~.:.uu.:.:~.:.uu.:.:.:.:.:.:.:<~:.:.:.:.:.:.:.:.:<~:.:.:.:.:.u
`
`~-;.;.;.;.;.;,:.;..;.;.;.;.;.;.;.;.:<-:.;.;.;.;.;.;.:<-:.;.;.;.;.;.:-:<-:..;.;.;.;.;.:-:<-:-:-:­
`~-:-:-:-:.:-:<-:..;.;.;.;.;.:-:-:-:<-:-:-:-;.:-:-:-:<-:-:-;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.:->:-:-:-:<
`
`;.;.;.;.;.;.;.;.;.;.;.;.;.;.:-:·:·:<·:·:·:·:-:·:·:·:<·:·:·:·:·:·:·:·:-:·:·:·:·:·:·:·:·:-:·:·:·:·:·:·;.:-:·:·:<·:·:·:·X·
`~:~:~~:~:~:~~:;~:~:~:~:~~:~:;:;~:~:~:~:~~:~:;:;~:~:~:~:~~:;:;:;~:~~:~:~~:;:;:;~:~~:~:~:~:~;:;:~:~~:~:~:~:~;:;:~:~<-:-
`······················································
`:-;-;-:·:·:·:-;·:-:·:·:·:·;-:·:·:·:<·:·:·:·;-:·:·:·:<·:·:·:·;-:·:·:·:-;·:-:·:·;-:·:·:·:-;·:-:·:·:·:·;-:·:·:·:<·:·:·:·;-:·;·;·;<(·:·:·;-;
`:%-.;~-.-.-.........-.;-.;-.-.;-...;......-.;-.;-.-.;-...;......-.;-.;-.;-.;-...;......-.;-.;-.;-.;-.-.;.........,;-.;-.;-.-.;-...;·
`;~;-;•;o;•;-.;o;o;•;•.•;•;o;•;-.;-.;.,;•;•.•;•;o;•;-.;-.;.,;•;•.•;•;o;•;-.;-.;.,;•;-:•;•;o;•;-.;-.;.,;•;-:•;•.•;•;.;.oo.,;•;<(.•;•.•;•;.;.oo.,;•;<(.•;•.•;o;
`~-.;•;-;•;o;o;<(.o;o;o;•,•;•;o;o;o;o;<(.o;•,•;•;o;o;o;o;<(.o;•,•;•;o;o;-.;o;<(.o;o;•;•;o;o;-.;o;<(.o;o;•;•,•;o;o;o;o;o;<(.•;•,•;o;o;o;o;o;<(.•;•,•;o;o;o;-.;o;<(.
`~!ISSSSSSS!;!·S~;!;o;ss!;!·S~;!;o;ss!;!•S!>'!>!ISSSSSS!>'!>!ISSSSSS!>S~IS~;·;~;ss!>S~IS~;·;~;ss!>S~ISSSS5
`::o~:o.'o:O:O:O:O:O!o:O:lo:O'o:0):0!o:O:lo:O'o:0):0!o:0:6:0.'o:0):0!o:o:Uo.'o:0):0!o:0:>:0~:0.,:0):0:>:0~:0.,:0):0:>:0~Uo.'o:O~
`:;:;~:;~~~~~~;:;:~;:;:~~~;:;:~;:;:~~~;:;:~~~~~~~;:~;:~~~~~~;:~;:~~;:~::;:~;:~~;:~::;:~;:~~;:;:~:;:~;:~~;.;.
`~-:.:-;.;.;.;.;.;.;.;.;.;.:-:·:·:·>:-:-:-:.:-:·:·:·>:-:-:-:.:-:..;.;.;.:.;.;.;.:-:..;.;.;.:.;.;.;.:-:.:-:·:·:·>:·:-:-:.:-:·:·:·>:·:-:-:.:-:-:-:-:..:-:.:-:.:-:-:-:
`::.:-:-:-:·:·~:-:.:·:·:·:.:·:·:·:·>:·:·:·:.:·:·:·:·>:·:·:·:-:·:-:·:·:-:·:.:·:-:·:-:·:·:-:·:.:·:·:·:.:·:·:·:·>:·:·:·:.:·:·:·:·>:·:·:·:-:·:-:·:·~:-:.:-:-:-:-:·:·~:0:
`::-x-:-:-:-:-:-»:-:-x-:-:-:->:-:-:-x-:-:-:->:-:-:-x-:-.-.:-:-:->:-»:-. .. :-:-:->:-:-:-x-:-:-:->:-:-:-x-:-:-:->:-:-:-x-:-:-:-:-:->:-»:-:-:-:-:->:-:(cid:173)
`::-:<·:-:·:«·:O:·:·:·:<·:«·>:·:·:·:<·:«·>:·:·:·:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:-:·:·:·:<·»:·>:·:·:·:<·»:·>:·:·:·:-:-»:·:-:-:-:-:-:-»:·:-:-:-:~
`~-:-:-:-:·:·:-:·:·:·:·:•:oi:•:-:-:·>:·:·:•:oi:•:-:-:·>:·:·:·:·:•:oi:•:•>:·:·:·:·:•:oi:•:•>:·:·:·:·:·:-t•:-:-:·>:·:·:·:-t•:-:-:·>:·:·:·:·:·:-:·:·>:·:·:·:·:·:-:·:·>:·:·:·:·
`;:-:.;:•:-:•:•:-:•:-:•:-:•:.:·:·:·:·>:•:-:•:.:·:·:·:·>:•:-:•:oi:•:-:•:•:-:•:-:•:oi:•:-:•:•:-:•:-:•:-:•:.:·:·:·:·>:•:-:•:.:·:·:·:·>:•:-:•:oi:•:-:•:•:-:•:-:•:oi:•:-:•:•:-:•:-:·:·:·:.:·:·~
`;:•:•:•:-:•:•:-:•:·:·:·:•:-:•:•:•:•l-:•:·:•:-:•:•:•:•l-:•:·:•:•:•:-:•:•:-:•:·:•:•:•:-:•:•:-:•:·:·:·:•:-:•:•:•:•l-:•:·:•:-:•:•:•:•l-:•:·:•:•:•:•:•:•:-:•:·:•:•:•:•:•:•:-:•:·:·:·:•:<•:•:•:•l-:
`::·:·:·:-:•:•:-:o:·:·:·:·:<•:•:-:ol-:·:·:·:<•:•:-:ol-:·:·:·:·:·:-:o;o:-:•:·:·:·:·:-:o;o:-:•:·:·:·:·:.;o;o:•:•l-:·:·:·:.;o;o:•:•l-:·:·:·:o:o:-:•:•:-:•:·:·:o:o:-:•:•:-:•:·:·:·:ox•:•:•:•:-:•:•:o
`~:::::~:::~:::::::::::~:::::::;:::::::~:::::::;:::::::::::~:::~:::::::::::~:::~:::::::::::~:::::::;:::::::~:::::::;:::::::::::~:::~::;:::::::~:::~::;:::::::~:::::::!::::::
`~·:·:·;",•;•:-:•:·:·:·:·;",•;•:•:·-::·:·:·;",•;•:•:·-::·:·:·:·:·;",•;•-::·:·:·:·:·;",•;•-::·:·:·:·:·;",•;•:•;•-:;•;•;•;",•;•:•;•-::·:·:·:·:•;",•;•;o;•;•;•;•;•;",•;•;o;•;•;•;•;•;",·;·:·:·'l:·:·:•;",•;
`:~~ .. ~~~~~~~~~~~~~~~~~~~~~~~~~ .. ~~~~~~~ .. ~~~~~~~~~~~~~~~~~~~~~~~~~ .. ~~~~~~~ .. ~~~~~~~~~~~~~~~~
`::·:·:·;",•;•;o;•;•;•;•;•;",•;•;•;•-:;•;•;•;",•;•;•;•-:;•;•;•;•;•;",•;•;o;•;•;•;•;•;",•;•;o;•;•;•;•;•;",•;•;•;•-:;•;•;•;",•;•;•;•-:;•;•;•;•;•;",•;•;o;•;•;•;•;•;",•;•;o;•;•;•;•;•;",•;•:•;•-::·:·:•:",•;•:•:•
`
`;.!.:.!o.'o!o!<o!O:o!O:o!o!o!o.'o!o!UO:o!o!o!o.'o!o!UO:o!.:.!o.'o!o!UO:o!.:.!o.'o!o!UO:o!O:o!o!o!o!o!•Uo!O:o!o!o!o!o!•Uo!O:o!.:.!o.'o!o!UO:o!.:.!o.'o!•Uo!O:o!O:o!o!o!o!o!•Uo!O:o!o!o!o
`;..;->:..;-:..;..;..;.u.:..;..,..;..;..;.:u.:..;.,.u-:.:u.:..;«..;-:.:-:..;.:..;«..;-:.:-:.:.:.:.:.:o!o!.:-:.:u.:.:o!o!.:-:.:u.:.:«.:-:.:-:.:.:.:«.:-:.:-:.:.:.:.:.:o!o!.:-:.:-:.u.:o!o!·
`:.:«.:-:.:-:.:.:.:.:.:o!o!.:-:.:u.:.:o!o!.:-:.:u.:.:« .. 'o!.:-:.:.:.:« .. 'o!.:-:.:.:.:.:.:o!o!.:-:.:u.:.:o!o!.:-:.:u.:.:«.:-:.:-:.:.:.:«.:-:.:-:.:.:.:.:.:o!o!.:uu.:.:o!o!.:uu.:.:.:
`~.;.;.;.~;.;~_;;.;;.;.~;.;.;.;~_;;.;.~;.;.;.;~_;;.;.;.;.~;.;g.;.;.;.~;.;g_;;.;.~;.;.;.;~.;;.;.~;.;.;.;~.;;.;.;.;.~;.;~.;;.;.;.;.~;.;~.;;.;;.;.~;.;.;.;~.;.;.;.;.;.;.;.;
`;.;.;.;.;.;.;.;.;..;.;.;.;.;.;.;.;.:-t-:.;.;.;.;.;.;.:-t-:.;.;.;.;.;.;.;.;.;..;.;.;.;.;.;.;.;.;..;.;.;.:->:-:-:-:-t-:-:-:->:-:-:-:-t-:.;.;.;.;.;.;.;.;.;..;.;.;.;.;.;.;.;.;..;.;.;.;.);.;.;.:-t•:-:-:->:·:·:·:<·:·
`;.;.;.;.;.;.;.;..;.;.;.;.;.;.;.;.;-:...;.;.;.;.;.;.;-:...;.;.;.;.;.;.:.;.;.;..;.;.;.;.;.:.;.;.;..;.;.;.;.,.;.;.;.:<-:-:-:-x-:-:-:<-:-:-:-:.;.;.:.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.:<-:-:.;.;.;.
`;.;.;.;.;.;.;.;:.;.;.;.;.;.;.;.;.;.:-t-:-:-:-;.;.;.;.:-t·:·:·:·:·:·:·:·:.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;(.;.;.;.;.;.;.;.;(.;.;.;.;.;.;.;.;(.;.;.;.;.;.;.;.;(.;.;.;.;.;.;..;.;.;.;(.;.;.;.;..;.;.;.;
`
`~-:-:-:-;.;.;.;.;..;.;.;.:->:-:-:-:<-:-:-:->:-:-:-:<-:-:-:-:-:-;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.;.);.;.;.;.-.;.;.;.);.;.;.;.-.;.;.;.;.;.;.;.;.;.;..;.;.;.;.;.;.;.;.;..;.;.;.:->:-:-:-:<·:-:-:->:·:·:·:<·:·
`
`:·:·:·:·:-:•:.:·:·:·:·:·:·:-:·:·:·:.:·:·:·:·:-:·:·:·:.:·:·:·:·:·:·:-:•:.:·:·:·:·:·:·:-:•:.:·:·:·:·:·:·:-:·:·:·:.:·:·:·:·:-:·:·:·:.:·:·:·:·:·:·:-:•:.:·:·:·:·:·:·:-:•:.:·:·:·:·:·:·:-:·:·:·:.:·:·:·:·:-:·:·:·:.:·:·
`:•:•:•:•:•:•:o;•:•:•:•:•:•:•:•:•:•;<(.•;•:•:•:•:•:•:•;<(.•;•:•:•:•:•:•:•:o;•;•:•:•:•:•:•:•:o;•;•:•:•:•:•:•:•:•:•;<(.•;•:•:•:•:•:•:•;<(.•;•:•:•:•:•:•:•:o;•;•:•:•:•:•:•:•:o;•;•:•:•:•:•:•:•:•:•;<(.•;•:•:•:•:•:•:•;<(.•;•:•:•:•:•:•:•:o;·
`
`;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;-;
`;o;o;o;o;.;o;.;o;o;o;o;o;o;.;o;o;o;.;o;o;o;o;.;o;o;o;.;o;o;o;o;o;o;.;o;.;o;o;o;o;o;o;.;o;.;o;o;o;o;o;o;.;o;o;o;.;o;o;o;o;.;o;o;o;.;o;o;o;o;o;o;.;o;.;o;o;o;o;o;o;.;o;.;o;o;o;o;o;o;.;o;o;o;.;o;o;o;o;.;o;o;o;.;o;o;o;o;o;o;.;o;.;.
`:.;·:·:-;.;-;-:-:-:-;-:-:->;·:·:·:<·;-:-:->;·:·:·:<·;-:-:-:-;-:-:·:<·;-:-:-:-;-:-:·:<·;-:-:-:-;-:-:·:·:·;<·:-:-;-:-:·:·:·;<·:-:-;-:-:·x-;.;-:-:-;-:-:·x·;-:-:-:·;·:·:·x·;·:·:-:·;·:·:·x·;·:·:-:·;-:-:-;.;-;.:-:.;:-;-:-:-:-;·
`
`~:~~:~:~:~m:~:::~:~~:~:;:;~:~:::~:~~:~:;:;~:~:::~:~~:~:;:;~:~~:~:~~:~:;:;~:~~:~:::~:~;:;~:~~:~:::~:~;:;m:~:::~:~;:;:~:~m:~:~;:;:~:~m:~:::~:~~:~m:~:::~:~~:~m:~~:~:~~:~:~:~m:~:~~:~:~~
`
`~ssss~:ssss:.s~:s~:-:sss:.s~:s~:-:sss:.sss~;ssssssss~;ssssss:.s~:ss-:sss:.s~:ss-:sss:.sssssssssssssssssss:.s~:ss-:sss:.s~:ss-:ssssssss.-.ssssssss.-.sss·
`
`0
`0
`
`'*-
`
`0
`1.11
`
`'*-
`
`I-"
`0
`
`'*-
`
`z
`QJ
`!:!".
`0
`:::s
`QJ
`
`Vl
`:::r
`....,
`QJ
`(!)
`
`n
`< Vl
`n
`....,
`QJ
`(!)
`3
`....,
`QJ
`A"
`
`(")
`
`tA -· ::s
`(I) --<
`
`Q) Q)
`
`s:::: ::s
`s::::
`(I)
`(")
`::::r-
`C"
`'<
`:.e
`
`(I)
`(I)
`~
`
`-· 3
`3
`(I) c.
`
`r::
`:::l
`c;J
`en r+
`.... -· n r+
`(I) c.
`
`-0 en r+
`
`PTX0892-00006
`
`6
`
`

`

`.......
`0
`0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`Strengthen formulary position is key
`Correlation between market share and market access ~ improvement in formulary
`position among payors with restrictions on Dymista is key
`Market share by plan (TRx)
`
`• t '
`D
`.... ym1s·a
`
`3.2%
`
`3.5%
`
`3.0%
`
`2.5%
`
`2.0%
`
`1.5%
`
`1.0%
`
`0.5%
`
`0.0%
`
`1.5%
`
`1.4%
`
`Humana
`
`Aetna
`
`BS of CA
`
`United Healthcare
`
`• 3.8 MM
`
`• National
`
`• Tier 2
`preferred
`
`• 8.4 MM
`
`• National
`
`• Tier 3
`unrestricted
`
`• 0.6 MM
`
`• Regional
`
`• Tier 3 with
`a single
`steo edit
`
`• 18 MM
`
`• National
`
`• Product not
`covered
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480367
`
`7
`
`

`

`Leverage recent formulary wins
`38 MM more Tier 2 Preferred (unrestrcited access) lives since April 2014 ~track
`record with Humana indicates the potential within this universe
`
`00
`0
`0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`Humana development vs.
`Meda US national average
`
`~
`
`/;;//~
`
`4.0%
`
`3.5%
`
`3.0%
`
`2.5%
`
`2.0%
`
`1.5%
`
`1.0%
`
`0.5%
`
`0.0%
`
`~
`~ ~ ~ ~ ~ ~ ~ ~ ~
`<.: "'>-
`<.: "'>-
`'!-: "'>- ~ "'.; ~ "'>-
`X.:"'>-
`'.$;) "'>-
`X.:"'>-
`'!-: "'-;
`'.$;) "'-;
`& ~ ~ ~ ~ ~ & ~ ~ ~
`
`&,.,.,.".,.,.,.,., .. Humana
`
`"""""·"· National Share
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480368
`
`8
`
`

`

`0')
`0
`0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`Market access threshold (YTD May 2014)
`
`• There is a threshold of unrestricted coverage(> 60%) to be reached
`where doctors will start prescribe a drug without hesitation
`
`• Dymista® has reached this threshold on national level in the
`commercial segment
`• National Average Unrestricted Access = 65% (States below National
`Average for access highlighted)
`
`• There is a correlation between unrestricted market access and market
`share among the US states
`- 7 4o/o of commercial lives unrestricted - 3.16o/o market share
`- Texas:
`- Oregon: - 41 °/o of commercial lives unrestricted - 0.39o/o market share
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480369
`
`9
`
`

`

`Dymista Unrestricted Access- Commercial Segment
`Percentage of Lives and Market Share
`
`0
`"""" 0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`AK-80%
`MS =.16%
`
`Dymista Nat. Mkt. Share= 1.47% (MS)
`Unrestricted Access Nat Avg. >= 65%
`
`,
`
`c~
`
`Hl-72%
`MS=3.69%
`
`ce~
`
`Managed Markets Insights & Technologies, July 2014
`
`Coverage/ MS
`NJ- 77% 13.38%
`MA- 37% I .34%
`DE- 70% I 2.23%
`CT- 68% /1.67%
`MD-55% /2.29%
`NH-82% I . 73%
`Rl-71% /1.05%
`VT-84% I .30%
`
`Limited Access to Providers
`
`No/minimal Rep Coverage
`
`PR-78%
`MS =3.1%
`
`h
`
`v
`
`TX-74%
`MS =3.16%
`
`\{
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480370
`
`10
`
`

`

`""""
`"""" 0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`• t '
`D
`.... ym1s·a
`Market share in the US is at European level when
`adjusting figures to unlimited market access
`
`···········-·-·-· ·-·-·-·-·-·-·-·-· ·-·-·-·-·-·-·--- -~--~---·---~---~--~ ---·-·-·-·-·-·-·-·
`
`Footnote :
`•
`Source: I MS data for end June, 2014, for R1 A 1 market
`•
`Sweden includes Rx only
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480371
`
`11
`
`

`

`N
`"""" 0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`Summary
`
`• Dymista® has achieved unrestricted coverage in 1 07 million
`lives which represents 1/3rd of the population (all segments)
`- 42 Million lives in a preferred tier 2 position (commercial) which represents
`13% of the overall U.S. population
`
`• There is a threshold of unrestricted coverage to be reached
`where doctors will start prescribe a drug without hesitation ->
`60°/o
`
`• Dymista® has reached this threshold at national level with 65o/o
`on average in the commercial segment
`
`• US Performance is at EU level when adjusting figures to
`unrestricted coverage (compare apples with apples)
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480372
`
`12
`
`

`

`D
`-
`
`• t F
`
`I
`
`p
`
`-
`
`Plan - Commercial
`Aetna
`California Blue Shield
`
`Care mark
`Cigna
`
`Express Scripts I Medco
`Harvard Pilgrim
`Health Alliance
`Health Net
`Health Partner
`Humana
`Independent Health
`Medlmpact
`Navitus
`
`Prime Therapeutics
`ProCare
`Rx Solutions (Now Optum Rx}
`Select Health
`
`Plan- Medicare Part D
`AARP (OptumRx)
`CIGNA
`
`CVS Caremark
`Express Scripts I Medco
`Humana
`
`T__'lQ_e
`MHC
`MHC
`
`PBM
`
`MHC
`
`PBM
`MHC
`MHC
`MHC
`MHC
`MHC
`MHC
`PBM
`PBM
`
`PBM
`PBM
`PBM
`MHC
`
`lives
`8,400,000
`3,000,000
`
`60,000,000
`
`6,500,000
`
`90 000 000
`1,100,000
`285,000
`2,100,000
`680,000
`3,800,000
`495,000
`6,000,000
`110,000
`
`20,000,000
`4,800,000
`4,000,000
`550,000
`
`~ lives
`MHC
`6,700,000
`MHC
`860,000
`
`M
`"""" 0
`0
`0
`I
`N
`0')
`00
`
`0 >< I-
`
`C..
`
`•t•
`
`D'{mista
`2014
`Rebates
`0%
`12%
`
`15%
`
`0%
`
`59%
`47%
`0%
`0%
`0%
`27%
`0%
`0%
`0%
`
`20%
`25%
`0%
`0%
`D'lmista
`2014
`Rebates
`59%
`54%
`
`2014 Final
`Placement
`Tier 3
`Tier 3
`
`Restricted
`
`Tier 3
`
`Tier 2
`Tier 2
`NDC Blocked
`Tier 3
`NDC Blocked
`Tier 2
`Tier 3 PA
`Prior Auth
`PA
`
`Tier 3
`Tier 2
`NDC Blocked
`Tier 3
`
`2014 Final
`Placement
`Preferred
`Preferred
`
`d Reb tes
`
`2014 Restrictions
`
`Step Edit
`
`60% of lives
`
`as of 511/14
`As of711l14
`Prior Auth
`None
`Prior Auth
`None
`Prior Auth
`Prior Auth
`Prior Auth
`
`None
`None
`NDC Blocked
`None
`
`2014 Restrictions
`None
`None
`
`PBM
`PBM
`MHC
`
`3,600,000
`2,700,000
`5,500,000
`
`0%
`59%
`53%
`
`Non Formulary
`Preferred
`Preferred
`
`Prior Auth
`None
`None
`
`HIGHLY CONFIDENTIAL-
`SUBJECT TO STIPULATED PROTECTIVE ORDER
`
`MEDA_APTX02480373
`
`13
`
`